Purpose: To assess concordance regarding proposed interactions between enzyme-inducing antiepileptic drugs (EI-AEDs) and direct oral anticoagulants (DOACs) in leading, international drug compendia.
Methods: We measured consistency of interaction reporting for each DOAC with a group of potent EI-AEDs among eight provider and consumer-focused drug compendia. Discrepant severity ranking systems were consolidated on a 0 to 4 scale. Percent agreement (PA) and Scott/Fleiss' Kappa (к) were used to quantify inter-compendia agreement on interaction listings, with linear weighting when consolidated severity rankings were taken into account (wPA and wк, respectively).
Results: For dabigatran, rivaroxaban, apixaban, and edoxaban, poor inter-compendia concordance was observed for interaction listings with EI-AEDs, with and without accounting for severity rankings (wPA: 0.54-0.72/wк: -0.08-0.03, and PA 0.47-0.79/к: -0.09-0.09, respectively). Conversely, betrixaban was consistently listed as not interacting with EI-AEDs in almost all assessed compendia, despite overlap in P-glycoprotein-based transport with other DOACs. Only 6/20 (30%) EI-AED/DOAC interactions were listed in all eight databases, and even in these six cases, severity rankings were universally discordant. Extreme inconsistencies in interaction reporting (some compendia assigning the highest possible severity ranking, while others reported no interactions) were observed in half of the individually examined interactions (10/20).
Conclusions: Drug compendia are highly inconsistent in the inclusion and reported severity of interactions between EI-AEDs and DOACs. Generation of high-quality, real-world evidence from large-scale outcome studies is imperative to resolve discordance and provide clarity for clinical guidelines.
Keywords: antiepileptic drugs; direct oral anticoagulants; drug compendia; drug-drug interactions; pharmacoepidemiology; thromboembolic events.
© 2019 John Wiley & Sons, Ltd.
Drug interactions involving antiepileptic drugs: assessment of the consistency among three drug compendia and FDA-approved labels.Epilepsy Behav. 2015 Mar;44:218-24. doi: 10.1016/j.yebeh.2015.02.009. Epub 2015 Mar 12. Epilepsy Behav. 2015. PMID: 25771206
Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).CNS Drugs. 2019 Dec;33(12):1223-1228. doi: 10.1007/s40263-019-00677-5. CNS Drugs. 2019. PMID: 31686406
Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs.Front Neurol. 2018 Dec 7;9:1067. doi: 10.3389/fneur.2018.01067. eCollection 2018. Front Neurol. 2018. PMID: 30581412 Free PMC article. Review.
Approaches to Direct Oral Anticoagulant Selection in Practice.J Cardiovasc Pharmacol Ther. 2018 Aug 9:1074248418793137. doi: 10.1177/1074248418793137. Online ahead of print. J Cardiovasc Pharmacol Ther. 2018. PMID: 30092658
Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants.J Pers Med. 2019 Jan 17;9(1):7. doi: 10.3390/jpm9010007. J Pers Med. 2019. PMID: 30658513 Free PMC article. Review.
- Stollberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98-101. https://doi.org/10.1016/j.eplepsyres.2016.06.003
- Clinical Key CP powered by. ©. 2019 Elsevier Inc. Vol 2019. https://www.clinicalkey.com/pharmacology/login.
- Comparisons DF&. ©. 2015 Clinical Drug Information, LLC. Vol 2019. http://online.factsandcomparisons.com.
- Lexicomp. © 2019 Wolters Kluwer Clinical Drug Information, Inc. and/or Its Affiliates. Vol 2019. https://www.uptodate.com/home/drugs-drug-interaction.
- Micromedex. © IBM Corporation 2019. Vol 2019. https://www.micromedexsolutions.com/micromedex2/librarian/ssl/true.